The Notified Body wants to see more. Recertification under the MDR runs until the end of 2027 or 2028, or a request with a deadline arrives. The gap cannot be closed with the old documentation.
Hospitals and registries document every day what your product achieves in real use. We unlock these data and turn them into studies that your Notified Body recognises, that convince physicians and that carry through to the guidelines.
The Notified Body wants to see more. Recertification under the MDR runs until the end of 2027 or 2028, or a request with a deadline arrives. The gap cannot be closed with the old documentation.
Off-label use: your product has long been used differently. Physicians use it in children or in indications that are not in the instructions for use and the intended purpose. Before anything happens, you need data for an extension of indication or a clear exclusion.
The health insurer wants the benefit proven. For reimbursement, what counts is data that show the benefit per case. Without it, your product remains a self-pay matter.
You lack sites for the first data. The product is new, and no hospital has documented it in a structured way so far. Then it starts with 2 or 3 sites that take part.
Real-World Evidence comes from data that is generated in routine care anyway: in hospital systems, patient records and registries. In an orthopaedic registry, for example, every implant has a record of how the operation went and how the patient is doing years later.
A randomised study is expensive, ends after a fixed period and often includes only a narrow slice of patients. Routine data, by contrast, shows long-term outcomes over 3 to 5 years and all patients, as they actually present in hospital. You can analyse subgroups specifically, such as children or patients with diabetes. And the MDR recognises such data as clinical data.
Level 1 of 5Hospital data
We establish which data your product needs by the next deadline, and in what order.
Level 1 · Hospital dataAnalysis of existing routine data from one or more sites, often the fastest route to robust evidence.
Level 2 · StudiesLong-term data from existing registries, cleanly analysed for your question.
Level 3 · AnalysisPlanning, conduct and analysis, including study protocol and ethics application. The data flows straight into your reports.
Level 4 · Clinical evaluationStudies rarely fail because of the idea. They fail because hospitals and physicians simply cannot manage them on top of their clinical duties and patient care. That is exactly where we help. I bring the sites: research-minded, motivated physicians in Germany and abroad who do research, publish and like to take part in studies. These opinion leaders often become the voices that later sit on guideline committees.
I follow up with your users, travel to the sites and make sure the participating physicians publish as co-authors. That is often the reason they take part. If you wish, we build and look after a network of key opinion leaders of your own.
Sites from our network, selection
The data often exists, and still nobody can get to it. The hospital administration hesitates, and data protection is unresolved. We prepare the ethics application, data protection, contracts and data processing agreement so that the hospital is legally covered and can approve. We go that route together with the physician who wants the study.

A wound therapy was used in patients with a left ventricular assist device, outside its original approval. The Notified Body required evidence under the MDR. We designed and carried out a retrospective study of 114 patients, supplemented by bench tests. The Notified Body received all the evidence it had asked for.
Read the full case study“The data we obtained gives us the confidence and clarity we need to use our technology in the demanding LVAD setting.”COO, wound therapy manufacturer
Answer 18 short questions about your product. You then receive your Evidence Plan as a PDF: which building blocks must be ready by your next deadline, when you have to start at the latest, and what budget to expect.

This is what your result looks like (example)
What manufacturers most often want to know before a study.

Yes, the MDR permits data from routine care as clinical data, for PMCF for example. What matters is that the study answers exactly the questions your Notified Body asks. We clarify that before the start.
For most questions after approval, no. Registries, routine data or a structured analysis of existing cases are often enough. In the evidence call we tell you honestly what is needed and what you can save yourself.
No, we deliberately do not. We deliver the data and the evidence that go into these reports, prepared so that your regulatory team can take them over directly.
A retrospective analysis of existing data can often be done in a few months. A new study has to enrol patients first, and that takes as long as it takes. In the plan you can see from the start what is realistic by your deadline.
In the evidence call, we look at your deadline and your data in 30 minutes. Afterwards you know which study you are missing next.